Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban in Type 2 Myocardial Infarctions: A Feasibility, Placebo-controlled, Double-blinded, Randomized Controlled Trial

NCT04838808 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT04838808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban in Type 2 Myocardial Infarctions: A Feasibility, Placebo-controlled, Double-blinded, Randomized Controlled Trial
Lead sponsor
University of Alberta
Phase
Phase 2/3
Overall status
Completed
Start date
April 5, 2021
Completion date
January 3, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type ii myocardial infarction